Atossa Therapeutics, Inc. (NASDAQ:ATOS) Short Interest Update

Atossa Therapeutics, Inc. (NASDAQ:ATOS) was the recipient of a significant drop in short interest in November. As of November 30th, there was short interest totalling 11,600,000 shares, a drop of 6.8% from the November 15th total of 12,450,000 shares. Based on an average daily trading volume, of 628,500 shares, the short-interest ratio is presently 18.5 days.

Institutional Trading of Atossa Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the business. XTX Topco Ltd acquired a new position in Atossa Therapeutics during the second quarter valued at $29,000. Intech Investment Management LLC purchased a new stake in shares of Atossa Therapeutics in the third quarter worth approximately $29,000. SG Americas Securities LLC boosted its holdings in shares of Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after purchasing an additional 30,037 shares during the period. Cetera Advisors LLC acquired a new stake in shares of Atossa Therapeutics during the first quarter worth approximately $72,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Atossa Therapeutics during the third quarter valued at approximately $75,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Stock Performance

Atossa Therapeutics stock opened at $1.04 on Wednesday. Atossa Therapeutics has a 52 week low of $0.70 and a 52 week high of $2.31. The firm has a market capitalization of $130.83 million, a price-to-earnings ratio of -4.73 and a beta of 1.21. The company has a 50 day moving average price of $1.34 and a 200 day moving average price of $1.32.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ATOS. Ascendiant Capital Markets upped their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a research report on Thursday, December 12th. Finally, StockNews.com cut Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.